{"generic":"Meningococcal Vaccine, Group B","drugs":["Bexsero","Meningococcal Vaccine, Group B","Trumenba"],"mono":{"0":{"id":"jy8bs0","title":"Generic Names","mono":"Meningococcal Vaccine, Group B"},"1":{"id":"jy8bs1","title":"Dosing and Indications","sub":{"0":{"id":"jy8bs1b4","title":"Adult Dosing","mono":"<ul><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Bexsero(R) (25 years or younger) 0.5 mL IM 2-dose series 1 month apart<\/li><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Trumenba(TM) (25 years or younger) 0.5 mL IM 3-dose series on a 0-, 2-, and 6-month schedule<\/li><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Do not use other meningococcal vaccines interchangeably to complete the vaccination series<\/li><\/ul>"},"1":{"id":"jy8bs1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Bexsero(R) (10 years or older) 0.5 mL IM 2-dose series 1 month apart<\/li><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Trumenba(TM) (10 years or older) 0.5 mL IM 3-dose series on a 0-, 2-, and 6-month schedule<\/li><li><b>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis:<\/b> Do not use other meningococcal vaccines interchangeably to complete the vaccination series<\/li><\/ul>"},"3":{"id":"jy8bs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Meningococcal infectious disease, Neisseria meningitidis group B; Prophylaxis<br\/>"}}},"3":{"id":"jy8bs3","title":"Contraindications\/Warnings","sub":[{"id":"jy8bs3b9","title":"Contraindications","mono":"Previous hypersensitivity or severe allergic reaction to meningococcal group B vaccine or any component of the vaccine <br\/>"},{"id":"jy8bs3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Syncope may occur<\/li><li>Immunologic:<\/li><li>-- Acute anaphylactic reaction may occur; monitoring recommended<\/li><li>-- Immunocompromised patients may have decreased immune response to vaccine.<\/li><li>-- Latex sensitivity; tip caps of the Bexsero(R) prefilled syringes contain natural rubber latex; Trumenba(TM) prefilled syringes do NOT contain natural rubber latex<\/li><\/ul>"},{"id":"jy8bs3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jy8bs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy8bs4","title":"Drug Interactions","sub":{"1":{"id":"jy8bs4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><\/ul>"}}},"5":{"id":"jy8bs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (14.9% to 50%), Injection site induration (28% to 32%), Injection site pain (83% to 92.8%), Swelling at injection site (18.2% to 21.6%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (18% to 19%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (13% to 21.6%), Myalgia (30.5% to 49%)<\/li><li><b>Neurologic:<\/b>Headache (34.8% to 54.8%)<\/li><li><b>Other:<\/b>Fatigue (35% to 62.4%), Feels cold (15.6% to 29%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"jy8bs6","title":"Drug Name Info","sub":{"0":{"id":"jy8bs6b17","title":"US Trade Names","mono":"<ul><li>Trumenba<\/li><li>Bexsero<\/li><\/ul>"},"2":{"id":"jy8bs6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jy8bs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy8bs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy8bs7","title":"Mechanism Of Action","mono":"Immunization with meningococcal group B vaccine is intended to stimulate the production of bactericidal antibodies against antigens comprised in the vaccine. The Trumenba(TM) vaccine has 2 antigens from factor H binding protein (fHbp) from serogroup B, 1 from subfamily A, and 1 from subfamily B (A05 and B01). The Bexsero(R) vaccine has antigens from Neisserial adhesin A (NadA), fHbp, and PorA P1.4 found in the outer membrane vesicles. Vaccination with meningococcal group B vaccine provides bactericidal protection against invasive disease by vaccine-derived antibody response.<br\/>"},"9":{"id":"jy8bs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For IM administration only<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>For IM administration only<\/li><li>Administer by IM injection, preferably in the deltoid muscle of the upper arm; shake well before use<\/li><li>Do not mix with other vaccines in the same syringe<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jy8bs10","title":"Monitoring","mono":"<ul><li>serologic response to the vaccine (eg, antibody titers) may indicate efficacy.<\/li><li>No specific monitoring has been determined.<\/li><\/ul>"},"11":{"id":"jy8bs11","title":"How Supplied","mono":"<ul><li><b>Bexsero<\/b><br\/>Intramuscular Suspension: 175 MCG\/0.5 ML<br\/><\/li><li><b>Trumenba<\/b><br\/>Intramuscular Suspension: 120 MCG\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"jy8bs13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include injection site pain, muscle pain, headache, fatigue, and chills.<\/li><li>Counsel patient on the importance of completing the entire immunization series.<\/li><\/ul>"}}}